MREO Receives Underweight Rating from JPMorgan as Analysts Weigh In

Mereo BioPharma Group's (MREO) stock has been assigned an 'underweight' rating by JPMorgan Chase & Co., a sentiment echoed in several other research reports. The biopharmaceutical company focuses on developing treatments for rare diseases, oncology, and severe respiratory conditions.

While some analysts have expressed optimism about Mereo's pipeline, including setrusumab (BPS-804) for osteogenesis imperfecta, others remain cautious. Zacks Research upgraded the stock from a 'strong sell' to a 'hold' rating in June, while Weiss Ratings reaffirmed a 'sell (e+)' rating in July.

Institutional investors hold a significant 62.83% stake in MREO, with notable positions being acquired by Marex Group plc and Squarepoint Ops LLC.